Issue link: https://www.e-digitaleditions.com/i/959280
Inhalation APRIL 2018 7 pletion of a multi-thematic special issue of the European Journal of Pharmaceutical Sciences (EJPS). Published in February 2018, the special issue features a collection of 14 scienti c articles that showcase the range of activities taking place under the auspices of SimInhale. Its intention is to provide a global view of the current state-of-the-art and, where possible, to highlight the in- terconnectedness and the links be- tween various topics. Approximate- ly one-third of the papers are critical reviews while the others are original research papers. A notable outcome showcased in the special issue is the SimInhale benchmark case, which we hope will aid the inhalation sci- ence community by providing a reference point for the validation of computer codes used in regional lung deposition studies in silico. An important SimInhale mission is to promote the integration of young researchers in the eld of in- haled medicines and to expose them to inter-sectoral training, thus preparing them for this highly multidisciplinary eld. Towards this goal, over the last two years, SimInhale has sponsored 13 Short Term Scienti c Missions (STSMs) with a budget of nearly €25,000. Upcoming events and activities In collaboration with the Faculty of Pharmacy of the University of Belgrade, SimInhale will organize a workshop titled, "Particle Engi- neering and Device Development for Pulmonary Drug Delivery: What is New?" Scheduled for pre- sentation in February 2018, it will focus on new activities in device and formulation development. Presenters will be pioneering researchers and experts from in- dustry and academia. In the rst week of September 2018, SimInhale will present a Summer School that will o er multidisciplinary short courses. e ve-day workshop will take place in Dublin, Ireland and the dates will be soon announced on the Action's website. SimInhale will be soon announcing a major inter- national conference that will take place in Cyprus in 2019 and will feature notable speakers from both industry and academia. For further information, see: • http://siminhale-cost.eu/ • COST Association website: www.cost.eu • LinkedIn: www.linkedin.com/ groups/8421105 • Facebook: www.facebook.com/ siminhale/ Acknowledgements is article is based upon work done in the framework of COST Action MP1404—SimInhale, sup- ported by COST (European Co- operation in Science and Technolo- gy). COST is a pan-European intergovernmental framework. Its mission is to enable breakthrough scienti c and technological devel- opments leading to new concepts and products and thereby contrib- ute to strengthening Europe's re- search and innovation capacities. Ben Forbes, PhD is Professor of Pharmaceutics at the Institute of Pharmaceutical Science, King's Col- lege London, London, UK. Andrea Danani, PhD is a Professor at the Dalle Molle Institute for Arti cial Intelligence (IDSIA), Università del- la Svizzera Italiana (USI), CH— 6928 Manno. Gerrit Borchard, PharmD, PhD is a Professor at the School of Pharmaceutical Sciences Geneva-Lausanne, (EPGL) Univer- sity of Geneva, University of Laus- anne, Geneva, CH. Stavros C. Kassinos, PhD is a Professor at the Computational Sciences Laboratory, School of Engineering, University of Cyprus, Nicosia, CY. Corresponding author: Stavros C. Kassinos, PhD, 1 University Avenue, 2109 Nicosia, Cyprus, +35722893528. CLIMATEZONE TM Climatically controlled environment for inhalation drug testing. • Controlled temperature and humidity • Closed loop HEPA filtered system • Safe environment for active drug handling • Suitable for inhalation drug handling • Mobile self contained system containment-technology.co.uk sales@containment-technology.co.uk ClimateZone TM